Does Rallies show Form 4 insider transactions for EBS?

Yes. Rallies tracks EBS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is EBS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EBS. It does not provide personalized investment advice.

EBS (Emergent Biosolutions, Inc.) Stock Analysis - Insider Trades

Emergent Biosolutions, Inc. (EBS) is a publicly traded Healthcare sector company. As of May 21, 2026, EBS trades at $8.26 with a market cap of $419.48M and a P/E ratio of -58.21. EBS moved +1.30% today. Year to date, EBS is -36.58%; over the trailing twelve months it is +17.44%. Its 52-week range spans $4.02 to $14.06. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces EBS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading EBS stock inside the company?

Recent EBS insider activity includes Dayal Sujata Tyagi sold 12.78K, Dayal Sujata Tyagi sold 980, DeGolyer Donald W sold 14.53K, DeGolyer Donald W sold 954, and Zoon Kathryn C sold 16.14K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

EBS Key Metrics

Key financial metrics for EBS
Metric	Value
Price	$8.26
Market Cap	$419.48M
P/E Ratio	-58.21
EPS	$-0.14
Dividend Yield	0.00%
52-Week High	$14.06
52-Week Low	$4.02
Volume	1.88K
Avg Volume	0
Revenue (TTM)	$676.80M
Net Income	$-8.60M
Gross Margin	54.24%

Recent EBS Insider Trades

Dayal Sujata Tyagi sold 12.78K (~$106.85K) on May 1, 2026.
Dayal Sujata Tyagi sold 980 (~$8.76K) on May 1, 2026.
DeGolyer Donald W sold 14.53K (~$121.45K) on May 1, 2026.
DeGolyer Donald W sold 954 (~$8.55K) on May 1, 2026.
Zoon Kathryn C sold 16.14K (~$134.97K) on May 1, 2026.

Latest EBS News

Emergent BioSolutions Q1 Revenue Beats Guidance as Debt Drops 22% — May 1, 2026
Emergent BioSolutions Secures $34.5M Deal to Manufacture JE Vaccine and Distribute to U.S. Government — Apr 28, 2026
Emergent BioSolutions Secures $150M Loan, Extends Maturities to 2031 and Cuts Interest 200bps — Apr 16, 2026
Emergent BioSolutions Rolls Out NARCAN Nasal Spray Carrying Case and 6- and 24-Unit Multipacks — Apr 7, 2026
Emergent BioSolutions Adds John Fowler to Board, Names Audit and Finance Committee Member — Mar 3, 2026

EBS Analyst Consensus

1 analysts cover EBS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about EBS

Who is trading EBS stock inside the company?: Recent EBS insider activity includes Dayal Sujata Tyagi sold 12.78K, Dayal Sujata Tyagi sold 980, DeGolyer Donald W sold 14.53K, DeGolyer Donald W sold 954, and Zoon Kathryn C sold 16.14K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for EBS?: Yes. Rallies tracks EBS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is EBS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EBS. It does not provide personalized investment advice.